Subscribe
istock-629430458pablo_k-1-
Pablo_K / iStockphoto.com
20 September 2018Americas

ERS extends CRISPR influence with two licensing deals

ERS Genomics and the Broad Institute of MIT and Harvard signed CRISPR licensing deals with Thermo Fisher Scientific on Tuesday, shortly before ERS expanded a separate agreement with Oxford Genetics.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
ERS Genomics signs CRISPR patent deal on industrial applications
16 October 2018   ERS Genomics, the company providing access to CRISPR/Cas9 IP owned by Emmanuelle Charpentier, has signed a licensing deal with synthetic biology startup Syngulon.
Americas
Amgen injects £50m in UK gene-sequencing company
19 October 2018   Amgen has invested £50 million ($66 million) in Oxford Nanopore Technologies, a UK company specialising in DNA/RNA sequencing technology.
Europe
ERS Genomics licenses CRISPR patents to Cambridge University spin-out
1 November 2018   The company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, ERS Genomics, has signed a patent licensing deal with DefiniGEN, a spin-out from the University of Cambridge, UK.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

More on this story

Europe
ERS Genomics licenses CRISPR patents to Cambridge University spin-out
1 November 2018   The company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, ERS Genomics, has signed a patent licensing deal with DefiniGEN, a spin-out from the University of Cambridge, UK.
Biotechnology
ERS Genomics signs CRISPR patent deal on industrial applications
16 October 2018   ERS Genomics, the company providing access to CRISPR/Cas9 IP owned by Emmanuelle Charpentier, has signed a licensing deal with synthetic biology startup Syngulon.
Americas
Amgen injects £50m in UK gene-sequencing company
19 October 2018   Amgen has invested £50 million ($66 million) in Oxford Nanopore Technologies, a UK company specialising in DNA/RNA sequencing technology.

More on this story

Europe
ERS Genomics licenses CRISPR patents to Cambridge University spin-out
1 November 2018   The company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, ERS Genomics, has signed a patent licensing deal with DefiniGEN, a spin-out from the University of Cambridge, UK.
Biotechnology
ERS Genomics signs CRISPR patent deal on industrial applications
16 October 2018   ERS Genomics, the company providing access to CRISPR/Cas9 IP owned by Emmanuelle Charpentier, has signed a licensing deal with synthetic biology startup Syngulon.
Americas
Amgen injects £50m in UK gene-sequencing company
19 October 2018   Amgen has invested £50 million ($66 million) in Oxford Nanopore Technologies, a UK company specialising in DNA/RNA sequencing technology.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York